Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.
Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, Forte L, Casalini P, Aiello P, Sfondrini L, Agresti R, Carcangiu ML, Plantamura I, Sozzi G, Tagliabue E, Campiglio M. Turdo F, et al. Among authors: plantamura i. Oncotarget. 2016 Oct 25;7(43):69649-69665. doi: 10.18632/oncotarget.11935. Oncotarget. 2016. PMID: 27626701 Free PMC article.
Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer.
Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM. Piovan C, et al. Among authors: plantamura i. Mol Oncol. 2012 Aug;6(4):458-72. doi: 10.1016/j.molonc.2012.03.003. Epub 2012 Apr 19. Mol Oncol. 2012. PMID: 22578566 Free PMC article.
PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.
Plantamura I, Casalini P, Dugnani E, Sasso M, D'Ippolito E, Tortoreto M, Cacciatore M, Guarnotta C, Ghirelli C, Barajon I, Bianchi F, Triulzi T, Agresti R, Balsari A, Campiglio M, Tripodo C, Iorio MV, Tagliabue E. Plantamura I, et al. Mol Oncol. 2014 Jul;8(5):968-81. doi: 10.1016/j.molonc.2014.03.015. Epub 2014 Mar 27. Mol Oncol. 2014. PMID: 24747080 Free PMC article.
miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.
D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, Tessari A, De Braud F, Di Leva G, Tripodo C, Iorio MV. D'Ippolito E, et al. Among authors: plantamura i. Cancer Res. 2016 Sep 15;76(18):5562-72. doi: 10.1158/0008-5472.CAN-16-0140. Epub 2016 Jul 11. Cancer Res. 2016. PMID: 27402080
miR-205 in Breast Cancer: State of the Art.
Plantamura I, Cataldo A, Cosentino G, Iorio MV. Plantamura I, et al. Int J Mol Sci. 2020 Dec 22;22(1):27. doi: 10.3390/ijms22010027. Int J Mol Sci. 2020. PMID: 33375067 Free PMC article. Review.
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV. Pizzamiglio S, et al. Among authors: plantamura i. Cancer Med. 2022 Jan;11(2):332-339. doi: 10.1002/cam4.4449. Epub 2021 Dec 17. Cancer Med. 2022. PMID: 34921525 Free PMC article. Clinical Trial.
14 results